MUMBAI, January 4, 2017 /PRNewswire/ --
- Seciera(TM) Meets Primary and Key Secondary Endpoints in Pivotal Trial
- Shows Efficacy at 12 Weeks of Treatment
- Sun Pharma is Developing Seciera(TM) for Global Markets
Sun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera(TM) (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease. Seciera(TM) is a patented, novel, proprietary nanomicellar formulation of cyclosporine A 0.09%. It is a clear, preservative-free, aqueous solution. Seciera(TM) is being developed by Ocular Technologies, a company recently acquired by Sun Pharma. Following this acquisition, Sun Pharma owns exclusive, worldwide rights to Seciera(TM) and is developing it to commercialize for global markets including US, Europe, and Japan, as well as several emerging markets.
(Logo: http://photos.prnewswire.com/prnh/20160711/813488 )
In this 12 week, multicenter, randomized, double-masked, vehicle controlled Phase 3 confirmatory study, 744 dry eye patients were treated either with Seciera(TM), or its vehicle. After 12 weeks of treatment, as compared to vehicle, Seciera(TM) showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p